In an exploratory randomised study of 18 patients with advanced hepatic malignancies, FOLactis plus PD-1 antibody with immunoradiotherapy had a target-lesion response rate of 33.3%; with low-dose chemotherapy, lesions did not shrink significantly. Group B had grade 1-2 fever.
RCTn = 18
Zhou et al. The safety and efficacy of in situ vaccine FOLactis for advanced hepatic malignancies